Maxime Dubosq-Lebaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maxime Dubosq-Lebaz has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Eric A. Secemsky
Harvard Medical School
6 shared publications - Jonathan Sobocinski
Department of Vascular Surgery, Aortic Centre, CHRU Lille, Lille, France
5 shared publications Louis Pruvot
4 shared publicationsRichard Azzaoui
4 shared publications- Raphaël Coscas
Department of Vascular Surgery, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France; Department of Vascular Surgery, American Hospital of Paris, Neuilly-sur-Seine, France; UMR 1018, Inserm-Paris11 - CESP, Versailles Saint-Quentin-en-Yvelines University, Paris-Saclay University, Paul Brousse Hospital, Villejuif, France
3 shared publications Yann Gouëffic
Department of Vascular and Endovascular Surgery Groupe Hospitalier Paris St Joseph Paris France
3 shared publications
Latest Publications
- 30 September 2026
- Published by Elsevier in The American Journal of Cardiology
- Vol. 280, 107-117
Drug-Eluting Resorbable Scaffolds for Infrapopliteal Peripheral Artery Disease: A State-of-the-Art Review
- 30 September 2026
- Published by Elsevier in The American Journal of Cardiology
- Vol. 280, 107-117
Drug-Eluting Resorbable Scaffolds for Infrapopliteal Peripheral Artery Disease: A State-of-the-Art Review
- 9 September 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (4) , 1063-1065
Covered stents for external iliac artery occlusive disease: Multicenter outcomes and predictors of reintervention
- 9 September 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (4) , 1063-1065
Covered stents for external iliac artery occlusive disease: Multicenter outcomes and predictors of reintervention
- 6 July 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (4) , 543-553
Carotid endarterectomy and stenting in France: A 10-year nationwide evaluation of practice and outcomes
Background: Carotid stenosis accounts for 20–30% of ischemic strokes. In France, management practices for symptomatic and asymptomatic disease remain heterogeneous. This study assessed the nationwide trends and outcomes of carotid endarterectomy (CEA) and carotid artery stenting (CAS) from 2011 to 2020. Methods: Using the French National Health Data System, we identified patients who underwent CEA or CAS for carotid stenosis. Symptomatic status was defined by stroke or transient ischemic attack within 6 months before intervention. Comorbidities were measured using the Charlson Comorbidity Index. The primary outcome was 30-day stroke or all-cause death. Results: Among 149,273 patients (85% asymptomatic), 4.8% of asymptomatic and 3.5% of symptomatic patients underwent CAS; the remaining patients underwent CEA. CAS recipients had greater comorbidity (Charlson ⩾ 3: 53% vs 39% in asymptomatic patients; 75% vs 66% in symptomatic patients). Thirty-day stroke/death occurred in 1.8% of asymptomatic patients (CAS 3.2% vs CEA 1.7%, p < 0.001) and 12.6% of symptomatic patients (CAS 15.5% vs CEA 12.6%). After multivariable adjustment, CAS was independently associated with higher risks of 30-day stroke and stroke/death compared with CEA. Five-year mortality was higher after CAS (28.5%) versus 20.9% after CEA. Cranial nerve injury was more frequent after CEA in symptomatic patients. Preoperative statin and antiplatelet use was lower in symptomatic patients (67.9% and 67.1%, respectively) versus asymptomatic patients (84.5% and 92.2%, respectively). Conclusions: CEA remains the predominant treatment for carotid stenosis in France, whereas CAS is mainly used in higher-risk patients. Early postoperative complications are more frequent in symptomatic cases, and lower preoperative medical therapy use highlights suboptimal secondary prevention in this group.
- 6 July 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (4) , 543-553
Carotid endarterectomy and stenting in France: A 10-year nationwide evaluation of practice and outcomes
Background: Carotid stenosis accounts for 20–30% of ischemic strokes. In France, management practices for symptomatic and asymptomatic disease remain heterogeneous. This study assessed the nationwide trends and outcomes of carotid endarterectomy (CEA) and carotid artery stenting (CAS) from 2011 to 2020. Methods: Using the French National Health Data System, we identified patients who underwent CEA or CAS for carotid stenosis. Symptomatic status was defined by stroke or transient ischemic attack within 6 months before intervention. Comorbidities were measured using the Charlson Comorbidity Index. The primary outcome was 30-day stroke or all-cause death. Results: Among 149,273 patients (85% asymptomatic), 4.8% of asymptomatic and 3.5% of symptomatic patients underwent CAS; the remaining patients underwent CEA. CAS recipients had greater comorbidity (Charlson ⩾ 3: 53% vs 39% in asymptomatic patients; 75% vs 66% in symptomatic patients). Thirty-day stroke/death occurred in 1.8% of asymptomatic patients (CAS 3.2% vs CEA 1.7%, p < 0.001) and 12.6% of symptomatic patients (CAS 15.5% vs CEA 12.6%). After multivariable adjustment, CAS was independently associated with higher risks of 30-day stroke and stroke/death compared with CEA. Five-year mortality was higher after CAS (28.5%) versus 20.9% after CEA. Cranial nerve injury was more frequent after CEA in symptomatic patients. Preoperative statin and antiplatelet use was lower in symptomatic patients (67.9% and 67.1%, respectively) versus asymptomatic patients (84.5% and 92.2%, respectively). Conclusions: CEA remains the predominant treatment for carotid stenosis in France, whereas CAS is mainly used in higher-risk patients. Early postoperative complications are more frequent in symptomatic cases, and lower preoperative medical therapy use highlights suboptimal secondary prevention in this group.
- Open Access
- 18 June 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (7) , 105458
Contemporary Indications for Bioresorbable Scaffolds for Infrapopliteal Peripheral Artery Disease: An International Expert Consensus
- 18 June 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (7) , 105458
Open AccessContemporary Indications for Bioresorbable Scaffolds for Infrapopliteal Peripheral Artery Disease: An International Expert Consensus
- 12 February 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 119
Evolving strategies for local drug delivery in peripheral arteries
- 12 February 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 119
Evolving strategies for local drug delivery in peripheral arteries
- 13 December 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (5) , 887-888
Early Clinical Experience with Intra-operative Cone Beam Computerised Tomography Using a Mobile C Arm System for Aorto-Iliac Endovascular Procedures
- 13 December 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (5) , 887-888
Early Clinical Experience with Intra-operative Cone Beam Computerised Tomography Using a Mobile C Arm System for Aorto-Iliac Endovascular Procedures
- 23 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (6) , 3355-3361
Long‐Term Outcomes of Jetstream Atherectomy Combined With Ranger Drug‐Coated Balloon in Calcified Femoropopliteal Lesions: A Three‐Year Single‐Center Experience
Background: Calcified femoropopliteal lesions remain a major challenge in peripheral endovascular interventions. Vessel preparation with atherectomy before drug‐coated balloon (DCB) angioplasty has been proposed to improve long‐term outcomes, but evidence remains limited. Aims: To evaluate the 3‐year clinical outcomes of Jetstream atherectomy combined with Ranger DCB angioplasty in patients with calcified femoropoplite. Methods: This retrospective, single‐center study included 50 patients (74% male, mean age 72.7 ± 9.8 years) treated between 2016 and 2020 for 63 femoropopliteal lesions. Lesions were classified as severely calcified in 56% of cases and TASC C‐D in 54%. Jetstream atherectomy was performed before Ranger DCB angioplasty. The primary endpoint was primary patency at 36 months, defined as freedom from restenosis or target lesion revascularization (TLR). Secondary endpoints included freedom from TLR and target vessel revascularization (TVR), Rutherford category and ankle‐brachial index (ABI) improvement, limb salvage, and all‐cause mortality. Results: TThe mean lesion length was 122.8 ± 78.9 mm. Bailout stenting was required in 6.3% of cases. Primary patency was 91.7% at 12 months and 69.2% at 36 months. Freedom from TLR was 98.4% at 12 months and 92.0% at 36 months. TVR freedom at 36 months was 82.0%. Rutherford improvement was observed in 92.0% of patients at 1 month and sustained in 84.0% at 36 months. ABI ≥ 0.9 was achieved in 69.4% at 1 month and 68.6% at 36 months. No major amputations or cardiovascular deaths occurred during follow‐up. Conclusion: Jetstream atherectomy combined with Ranger DCB angioplasty provided sustained long‐term patency, low reintervention rates, and durable clinical benefit in patients with calcified femoropopliteal lesions. Further prospective trials are needed to validate these findings.
- 23 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (6) , 3355-3361
Long‐Term Outcomes of Jetstream Atherectomy Combined With Ranger Drug‐Coated Balloon in Calcified Femoropopliteal Lesions: A Three‐Year Single‐Center Experience
Background: Calcified femoropopliteal lesions remain a major challenge in peripheral endovascular interventions. Vessel preparation with atherectomy before drug‐coated balloon (DCB) angioplasty has been proposed to improve long‐term outcomes, but evidence remains limited. Aims: To evaluate the 3‐year clinical outcomes of Jetstream atherectomy combined with Ranger DCB angioplasty in patients with calcified femoropoplite. Methods: This retrospective, single‐center study included 50 patients (74% male, mean age 72.7 ± 9.8 years) treated between 2016 and 2020 for 63 femoropopliteal lesions. Lesions were classified as severely calcified in 56% of cases and TASC C‐D in 54%. Jetstream atherectomy was performed before Ranger DCB angioplasty. The primary endpoint was primary patency at 36 months, defined as freedom from restenosis or target lesion revascularization (TLR). Secondary endpoints included freedom from TLR and target vessel revascularization (TVR), Rutherford category and ankle‐brachial index (ABI) improvement, limb salvage, and all‐cause mortality. Results: TThe mean lesion length was 122.8 ± 78.9 mm. Bailout stenting was required in 6.3% of cases. Primary patency was 91.7% at 12 months and 69.2% at 36 months. Freedom from TLR was 98.4% at 12 months and 92.0% at 36 months. TVR freedom at 36 months was 82.0%. Rutherford improvement was observed in 92.0% of patients at 1 month and sustained in 84.0% at 36 months. ABI ≥ 0.9 was achieved in 69.4% at 1 month and 68.6% at 36 months. No major amputations or cardiovascular deaths occurred during follow‐up. Conclusion: Jetstream atherectomy combined with Ranger DCB angioplasty provided sustained long‐term patency, low reintervention rates, and durable clinical benefit in patients with calcified femoropopliteal lesions. Further prospective trials are needed to validate these findings.